Clinical Trials Browser

INDUSTRY × camrelizumab × Thoracic × Clear all

NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Phase 2 Completed

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT04619433 2025-09-23

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Phase 3 Terminated

Non-squamous Non-small-cell Lung Cancer

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03417895 2024-08-07

PASSION

Phase 2 Completed

59 enrolled 17 charts

Small Cell Lung Carcinoma

NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Phase 2/3 Not yet recruiting

Non-squamous Non-small Cell Lung Cancer

NCT05841472 2023-08-30

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

Non Squamous Non Small Cell Lung Cancer

NCT05106335 2023-08-16

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Phase 3 Terminated

Advanced NSCLC

NCT03085069 2023-02-16

A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

Phase 2 Unknown

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Respiratory Tract Diseases

NCT05042375 2022-11-17

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03666728 2021-03-17

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Phase 2 Terminated

Lung Neoplasms

NCT03668496 2021-03-15

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

Phase 3 Unknown

Lung Neoplasms

NCT03134872 2020-06-09

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Phase 3 Completed

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04203485 2020-05-08

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 3 Unknown

PD-L1 Positive Non-small Cell Lung Cancer